
Keywords: BMD; bone mineral density; BZA; bazedoxifene; CE; conjugated estrogens; EPT; estrogen-progestin therapy; ER; estrogen receptor; LAS; lasofoxifene; LDL-C; low-density lipoprotein cholesterol; MCF-7; Michigan Cancer Foundation-7; MENQOL; Menopause-Specific